


BE IT KNOWN that I, Sunita Kumeri of, 268 Bath Road, Slough, Berkshire United Kingdom a duly authorised Notary Public

CERTIFY ONLY that Brian Michael Howes who is well known to me and who is duly authorised by GlaxoSmithKline ("the Company") to represent them in this matter has today caused the annexed Certificate of GMP Compliance of a Manufacturer issued to Nextpharma SAS to be produced to me and has represented to me on behalf of the company that the said document is a true copy of the original electronic document produced to him.



SIGNED and sealed at 268 Bath Road, Slough, Berkshire aforesaid on 8th January 2020.



Sunita Kumeri
Notary Public
England and Wales

Protocol No. 9120



APOSTILLE (Convention de La Haye du 5 octobre 1961)	
1. Country: Pays / Pais:	United Kingdom of Great Britain and Northern Ireland
This public document Le présent acte public / El presente documento público	
2. Has been signed by a été signé par ha sido firmado por	Sunita Kumeri
3. Acting in the capacity of agissant en qualité de quien actúa en calidad de	Notary Public
4. Bears the seal / stamp of est revêtu du sceau / timbre de y está revestido del sello / timbre de	The Said Notary Public
Certified Attesté / Certificado	
5. at à / en	London
6. the le / el día	09 January 2020
7. by par / por	Her Majesty's Principal Secretary of State for Foreign and Commonwealth Affairs
8. Number sous no / bajo el numero	APO-1788563
9. Seal / stamp Sceau / timbre Sello / timbre	
10. Signature Signature Firma	A. Hodges 

This Apostille is not to be used in the UK and only confirms the authenticity of the signature, seal or stamp on the attached UK public document. It does not confirm the authenticity of the underlying document. Apostilles attached to documents that have been photocopied and certified in the UK confirm the signature of the UK official who conducted the certification only. It does not authenticate either the signature on the original document or the contents of the original document in any way.

If this document is to be used in a country not party to the Hague Convention of the 5th of October 1961, it should be presented to the consular section of the mission representing that country

To verify this apostille go to www.verifyapostille.service.gov.uk

French National Agency for Medicines and Health Products Safety

CERTIFICATE NUMBER: 2019/HPF/FR/290

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER^{1, 2}

Part 1

Issued following an inspection in accordance with :
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of France confirms the following:

The manufacturer: **NEXTPHARMA SAS**

Site address: **17 route de Meulan, LIMAY, 78520, France**

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. **MM 16/214** in accordance with Art. 40 of Directive 2001/83/EC transposed in the following national legislation:

Art. L.5124-3 of Public Health Code

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2019-07-19**, it is considered that it complies with :

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC³

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

² Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products	
1 MANUFACTURING OPERATIONS	
1.2	Non-sterile products
	<i>1.2.1 Non-sterile products (processing operations for the following dosage forms)</i> 1.2.1.1 Capsules, hard shell 1.2.1.5 Liquids for external use 1.2.1.6 Liquids for internal use 1.2.1.9 Pressurised preparations 1.2.1.11 Semi-solids 1.2.1.12 Suppositories
	<i>1.2.2 Batch certification</i>
1.5	Packaging
	<i>1.5.1 Primary Packing</i> 1.5.1.1 Capsules, hard shell 1.5.1.5 Liquids for external use 1.5.1.6 Liquids for internal use 1.5.1.9 Pressurised preparations 1.5.1.11 Semi-solids 1.5.1.12 Suppositories
	<i>1.5.2 Secondary packing</i>
1.6	Quality control testing
	<i>1.6.2 Microbiological: non-sterility</i> <i>1.6.3 Chemical/Physical</i>

Clarifying remarks (for public users)

Signatory: Mr Said Ioughlissen, deputy head of the pharmaceutical product inspection and counterfeiting fight department --- The ANSM does not issue paper copies of good manufacturing practice certificates.

2019-10-23

Name and signature of the authorised person of the
Competent Authority of France

Confidential
French National Agency for Medicines and Health
Products Safety
Tel: *Confidential*
Fax: *Confidential*